{"id":987857,"date":"2026-07-31T07:03:11","date_gmt":"2026-07-31T11:03:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-receives-rd-rebates-of-approximately-4-6-million\/"},"modified":"2026-07-31T07:03:11","modified_gmt":"2026-07-31T11:03:11","slug":"inmune-bio-receives-rd-rebates-of-approximately-4-6-million","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-receives-rd-rebates-of-approximately-4-6-million\/","title":{"rendered":"INmune Bio Receives R&D Rebates of Approximately $4.6 Million"},"content":{"rendered":"
\n

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million.\u00a0 This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026.\u00a0 After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company’s net cash used in operating activities during the quarter.\u00a0 The rebates strengthen the Company’s balance sheet and extend its cash runway as INmune Bio advances CORDStrom\u2122 (Ebstrocel\u2122) toward regulatory filings.<\/p>\n

\u201cThese rebates are a meaningful financial milestone for INmune Bio and our shareholders,\u201d said David Moss, Chief Executive Officer of INmune Bio. \u00a0\u201cReceiving approximately $4.6 million in non-dilutive cash during June and July strengthens our financial position, extends our runway without issuing additional equity and allows us to preserve momentum across the near-term regulatory and clinical milestones that we believe can drive substantial value.\u00a0\u00a0 We are grateful for R&D incentive programs that recognize the significant investment required to develop new medicines. By supporting innovative biotechnology companies through long and capital-intensive development programs, these initiatives help advance promising therapies for patients with serious diseases and limited treatment options.\u201d<\/p>\n

The rebates were generated through established government programs designed to support qualifying research and development conducted in the UK and Australia. They reflect eligible expenditures related to the Company\u2019s clinical-development, manufacturing and regulatory activities in those jurisdictions.<\/p>\n

\n About\u00a0INmune\u00a0Bio Inc.<\/b>\n <\/p>\n

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company\u2019s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.<\/p>\n

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:<\/p>\n